Botulinum toxin treatment in parkinsonism
This article is a narrative review of the therapeutic use of BoNT in tremors, dystonia, sialorrhea, bladder and other autonomic symptoms, levodopa-induced dyskinesia and other problems occuring in the setting of parkinsonism. Though FDA approval is lacking for some of these indications, expert experiences have shown that BoNT is often beneficial in this group of patients.
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Charenya Anandan, Joseph Jankovic Tags: Review Article Source Type: research
More News: Brain | Carbidopa/Levodopa | Dyskinesia | Dystonia | Food and Drug Administration (FDA) | Neurology | Opthalmology | Strabismus (squint) | USA Health